你知道吗？支气管扩张症这种常见却又复杂的呼吸系统疾病，终于迎来了新的突破！近日，国际权威医学期刊《The Lancet respiratory medicine》（影响因子高达38.7）发表了钟南山院士团队的最新研究成果。而这项研究的背后，还有我们遂宁市中心医院呼吸与危重症医学科邱容主任团队的深度参与！

近日，国际权威医学期刊《The Lancet respiratory medicine 》（IF：38.7）在线发表了钟南山院士团队关于支气管扩张症（Bronchiectasis）的最新研究成果。 遂宁市中心医院呼吸与危重症医学科邱容主任团队作为共同第一作者参与该成果发表。

随着全球呼吸系统疾病负担日益加重，支气管扩张症（简称“支扩症”）等慢性气道疾病的治疗进展备受关注。支扩症长期面临针对性疗法匮乏的难题，严重影响患者的生活质量与健康。2025年3月，国际呼吸领域及危重症医学领域顶级顶刊《柳叶刀·呼吸病学》（The ...

支扩症是我国最常见的高度异质性气道炎症性慢病之一,其病程长、症状负担重且容易反复急性加重,严重影响了患者的生活质量,并对个人和社会造成巨大的经济负担。现有疗法多局限于症状缓解,稳定期预防急性加重药物长期匮乏。支扩症的核心病理机制为中性粒细胞过度活化, ...

The Lancet Respiratory Medicine published a phase 2 clinical study article on China's first DPP-1 inhibitor, HSK31858, led by ...

支扩症是我国最常见的高度异质性气道炎症性慢病之一，其病程长、症状负担重且容易反复急性加重，严重影响了患者的生活质量，并对个人和社会造成巨大的经济负担。现有疗法多局限于症状缓解，稳定期预防急性加重药物长期匮乏。支扩症的核心病理机制为中性粒细胞过度活化，其释放的弹性蛋白酶（NE）等破坏气道结构，形成“炎症-感染-再炎症”恶性循环。DPP-1作为激活释放中性粒细胞丝氨酸蛋白酶（NSPs）的关键酶，成为阻 ...

Over the past decades, bronchiectasis has been neglected, despite the global burden.1,2 To date, better diagnosis due to easy ...

Understanding the scale of the problem is the first step to addressing it. Scientists issue stark warning about growing ...

NightOwl is now widely available across the United States. Individuals interested in NightOwl should speak with their healthcare provider for more information. To learn more, visit: https://www.resmed ...

WHO issued a statement outlining the grave consequences of the US decision to drastically cut international funding for tuberculosis. WHO noted that countries with high burdens of tuberculosis disease ...

Hypoxemia is the most common complication of emergency endotracheal intubation of children, with an incidence of up to 50%.

Minister of State Environment Kirti Vardhan Singh told Parliament that air pollution was one of ‘many factors affecting ...